US2007048304A1PendingUtilityA1

Method of treating allergy using antibody against human interleukin-5 receptor alpha chain

61
Assignee: KYOWA HAKKO KOGYO KKPriority: Sep 11, 1995Filed: Nov 13, 2006Published: Mar 1, 2007
Est. expirySep 11, 2015(expired)· nominal 20-yr term from priority
Inventors:Masamichi KoikeAkiko FuruyaKazuyasu NakamuraAkihiro IidaHideharu AnazawaNobuo HanaiKiyoshi Takatsu
A61P 37/08C07K 2319/00C07K 14/7155A61K 2039/505C07K 16/2866C07K 2317/565C07K 2317/73A61K 38/00A61P 11/06C12N 2799/026C07K 2317/24C07K 2317/76C07K 2319/30C07K 16/28C12P 21/00
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides monoclonal antibodies and humanized antibodies which react specifically with a human interleukin-5 receptor α chain. The invention also provides hybridomas and transformants which produce the antibodies, the monoclonal antibodies and humanized antibodies, a method for detecting an interleukin-5 receptor α chain immunologically by means of these antibodies, as well as a method for diagnosing and treating diseases such as chronic bronchial asthma by means of the monoclonal antibodies and humanized antibodies. The present invention is useful for diagnosis or treatment of diseases such as chronic bronchial asthma.

Claims

exact text as granted — not AI-modified
1 - 58 . (canceled)  
     
     
         59 . A method for treating an allergic disease, comprising administering to a mammal in need thereof an effective amount of an antibody which recognize an epitope at position 1-313 from the N-terminal amino acid of a human interleukin-5 receptor a chain.  
     
     
         60 . The method of  claim 59 , wherein the antibody is selected from monoclonal antibody, humanized antibody, single chain antibody and disulfide-stabilized antibody.  
     
     
         61 . The method of  claim 60 , wherein the antibody is a monoclonal antibody.  
     
     
         62 . The method of  claim 61 , wherein the monoclonal antibody specifically binds to a human interleukin-5 receptor a chain on the surface of an immunocyte.  
     
     
         63 . The method of  claim 61 , wherein the monoclonal antibody inhibits the eosinophil survival time prolongation by human interleukin-5.  
     
     
         64 . The method of  claim 63 , wherein the monoclonal antibody belongs to IgG1 subclass, 
 CDR sequences in the V region of the H chain of the antibody comprise the following amino acid sequences:    CDR1: Ser Tyr Val Lle his (Seq ID NO: 40);    CDR2: Tyr Lle Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Arg Phe Lys Gly (Seq ID NO: 41); and    CDR3: Glu Gly Ile Arg Tyr Try Gly Leu Leu Gly Asp Tyr (Seq ID NO: 42);    and CDR sequences in the V region of the L chain comprise the following amino acid sequences:    CDR1: Gly Thr Ser Glu Asp Ile Ile Asn Tyr Leu Asn (Seq ID NO: 43);    CDR2: His Thr Ser Arg Leu Gln Ser (Seq ID NO: 44); and    CDR3: Gln Gln Gly Tyr Thr Leu Pro Tyr Thr (Seq ID NO: 45).    
     
     
         65 . The method of  claim 64 , wherein the monoclonal antibody is monoclonal antibody KM1259 produced by hybridoma KM1259 (PERM BP-5134).  
     
     
         66 . The method of  claim 63 , wherein the monoclonal antibody belongs to IgG1 subclass, 
 CDR sequences in the V region of the H chain of the antibody comprise the following amino acid sequences:    CDR1: Asp Thr Tyr Met His (Seq ID NO: 46);    CDR2: Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Ser Asp Pro Lys Phe Gin Ala (Seq ID NO: 47); and    CDR3: Gly Leu Arg Leu Arg Phe Phe Asp Tyr (Seq ID NO: 48); and    CDR sequences in the V region of the L chain comprise the following amino acid sequences:    CDR1: Ser Ala Ser Ser Ser Val Ser Tyr Met His (Seq ID NO: 49);    CDR2: Asp Thr Ser Lys Leu Ala Ser (Seq ID NO: 50); and    CDR3: Gln Gln Trp Ser Ser Asn Pro Pro Ile Thr (Seq ID NO: 51).    
     
     
         67 . The method of  claim 66 , wherein the monoclonal antibody is monoclonal antibody KM1486 produced by hybridoma KM1486 (FERM BP-5651).  
     
     
         68 . The method of  claim 60 , wherein the monoclonal antibody is a humanized antibody.  
     
     
         69 . The method of  claim 68 , wherein the humanized antibody reacts specifically with the human interleukin-5 receptor a chain by immunocyte staining.  
     
     
         70 . The method of  claim 68 , wherein the humanized antibody inhibits the eosinophil survival time prolongation by human interleukin-5.  
     
     
         71 . The method of  claim 69  or  70 , wherein the antibody belongs to human antibody IgG class.  
     
     
         72 . The method of  claim 68 , wherein the humanized antibody is a human chimeric antibody.  
     
     
         73 . The method of  claim 72 , wherein the human chimeric antibody is a chimeric antibody comprising the V region of the H chain and the V region of the L chain of a non-human animal antibody, as well as the constant region (C region) of the H chain and the C region of the L chain of a human antibody.  
     
     
         74 . The method of  claim 73 , wherein the V region of the H chain of the antibody comprises the amino acid sequences of SEQ ID NO: 27 and the V region of the L chain of the antibody comprises the amino acid sequence of SEQ ID NO: 29.  
     
     
         75 . The method of  claim 73 , wherein the V region of the H chain of the antibody comprises the amino acid sequence of SEQ ID NO: 31 and the V region of the L chain of the antibody comprises the amino acid sequence of SEQ ID NO: 33.  
     
     
         76 . The method of  claim 73 , wherein the antibody is antibody KM1399 wherein the C region of the H chain of the antibody is in human antibody IgG1 subclass.  
     
     
         77 . The method of  claim 73 , wherein the antibody is antibody KM7399 and the C region of the H chain of the antibody is in human antibody IgG4 subclass.  
     
     
         78 . The method of  claim 68 , wherein the humanized antibody is a human CDR-grafted antibody.  
     
     
         79 . The method of  claim 78 , wherein the human CDR-grafted antibody is obtained by replacing CDR sequences in the V region of the H chain and the V region of the L chain of a human antibody with CDR sequences in the V region of the H chain and the V region of the L chain of a non-human animal antibody.  
     
     
         80 . The method of  claim 79 , wherein the CDR sequences in the V region of the H chain of the antibody comprise the following amino acid sequences: 
 CDR1: Ser Tyr Val Lle his (Seq ID NO: 40);    CDR2: Tyr Lle Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Arg Phe Lys Gly (Seq ID NO: 41); and    CDR3: Glu Gly Ile Arg Tyr Try Gly Leu Leu Gly Asp Tyr (Seq ID NO: 42); and    the CDR sequences in the V region of the L chain of the antibody comprises the following amino acid sequences:    CDR1: Gly Thr Ser Glu Asp Ile Ile Asn Tyr Leu Asn (Seq ID NO: 43);    CDR2: His Thr Ser Arg Leu Gln Ser (Seq ID NO: 44); and    CDR3: Gln Gln Gly Tyr Thr Leu Pro Tyr Thr (Seq ID NO: 45).    
     
     
         81 . The method of  claim 79 , wherein the CDR sequences in the V region of the H chain of the antibody comprise the following amino acid sequences: 
 CDR1: Asp Thr Tyr Met His (Seq ID NO: 46);    CDR2: Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Ser Asp Pro Lys Phe Gin Ala (Seq ID NO: 47); and    CDR3: Gly Leu Arg Leu Arg Phe Phe Asp Tyr (Seq ID NO: 48); and    the CDR sequences in the V region of the L chain of the antibody comprise the following amino acid sequences:    CDR1: Ser Ala Ser Ser Ser Val Ser Tyr Met His (Seq ID NO: 49);    CDR2: Asp Thr Ser Lys Leu Ala Ser (Seq ID NO: 50); and    CDR3: Gln Gln Trp Ser Ser Asn Pro Pro Ile Thr (Seq ID NO: 51).    
     
     
         82 . The method of  claim 80 , wherein the antibody is antibody KM8399 and the C region of the H chain of the antibody belongs to human antibody IgG1 subclass.  
     
     
         83 . The method of  claim 80 , wherein the antibody is antibody KM9399 and the C region of the H chain of the antibody is in a human antibody IgG4 subclass.  
     
     
         84 . The method of  claim 60 , wherein the antibody is a single chain antibody.  
     
     
         85 . The method of  claim 84 , wherein the single chain antibody inhibits the eosinophil survival time prolongation by human interleukin-5.  
     
     
         86 . The method of  claim 84 , wherein the single chain antibody comprises the V region of the H chain the V region of the L chain of a humanized antibody.  
     
     
         87 . The method of  claim 84 , wherein the CDR sequences in the V region of the H chain of the single chain comprise the following amino acid sequences: 
 CDR1: Ser Tyr Val Lle his (Seq ID NO: 40);    CDR2: Tyr Lle Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Arg Phe Lys Gly (Seq ID NO: 41); and    CDR3: Glu Gly Ile Arg Tyr Try Gly Leu Leu Gly Asp Tyr (Seq ID NO: 42); and    the V region of the L chain of the single chain antibody comprise the following amino acid sequences:    CDR1: Gly Thr Ser Glu Asp  Ile  Ile Asn Tyr Leu Asn (Seq ID NO: 43);    CDR2: His Thr Ser Arg Leu Gln Ser (Seq ID NO: 44); and    CDR3: Gln Gln Gly Tyr Thr Leu Pro Tyr Thr (Seq ID NO: 45).    
     
     
         88 . The method of  claim 84 , wherein the CDR sequences in the V region of the H chain of the single chain antibody comprise the following amino acid sequences: 
 CDR1: Asp Thr Tyr Met His (Seq ID NO: 46);    CDR2: Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Ser Asp Pro Lys Phe Gin Ala (Seq ID NO: 47); and    CDR3: Gly Leu Arg Leu Arg Phe Phe Asp Tyr (Seq ID NO: 48); and    the V region of the L chain of the single chain antibody comprise the following amino acid sequences:    CDR1: Ser Ala Ser Ser Ser Val Ser Tyr Met His (Seq ID NO: 49);    CDR2: Asp Thr Ser Lys Leu Ala Ser (Seq ID NO: 50); and    CDR3: Gln Gln Trp Ser Ser Asn Pro Pro Ile Thr (Seq ID NO: 51).    
     
     
         89 . The method of  claim 60 , wherein the antibody is a disulfide-stabilized antibody.  
     
     
         90 . The method of  claim 89 , wherein the disulfide-stabilized antibody inhibits the eosinophil survival time prolongation by human interleukin-5.  
     
     
         91 . The method of  claim 90 , wherein the disulfide-stabilized antibody comprises the V region of the H chain and the V region of the L chain of a humanized antibody.  
     
     
         92 . The method of  claim 90 , wherein the CDR sequences in the V region of the H chain comprise following amino acid sequences: 
 CDR1: Ser Tyr Val Lle his (Seq ID NO: 40);    CDR2: Tyr Lle Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Arg Phe Lys Gly (Seq ID NO: 41); and    CDR3: Glu Gly Ile Arg Tyr Try Gly Leu Leu Gly Asp Tyr (Seq ID NO: 42); and    the V region of the L chain of the disulfide-stabilized antibody comprise the following amino acid sequences:    CDR1: Gly Thr Ser Glu Asp  Ile  Ile Asn Tyr Leu Asn (Seq ID NO: 43);    CDR2: His Thr Ser Arg Leu Gln Ser (Seq ID NO: 44); and    CDR3: Gln Gln Gly Tyr Thr Leu Pro Tyr Thr (Seq ID NO: 45).    
     
     
         93 . The method of  claim 90 , the CDR sequences in the V region of the H chain comprise the following amino acid sequences: 
 CDR1: Asp Thr Tyr Met His (Seq ID NO: 46);    CDR2: Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Ser Asp Pro Lys Phe Gin Ala (Seq ID NO: 47); and    CDR3: Gly Leu Arg Leu Arg Phe Phe Asp Tyr (Seq ID NO: 48); and    the V region of the L chain of the single chain antibody comprise the following amino acid sequences:    CDR1: Ser Ala Ser Ser Ser Val Ser Tyr Met His (Seq ID NO: 49);    CDR2: Asp Thr Ser Lys Leu Ala Ser (Seq ID NO: 50); and    CDR3: Gln Gln Trp Ser Ser Asn Pro Pro Ile Thr (Seq ID NO: 51).

Join the waitlist — get patent alerts

Track US2007048304A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.